BE(Hons), MBA, PhD, Hon DSc(Macq), Hon DSc(UNSW), FTSE, FAICD, Hon FIEAust
Dr Roberts is a highly experienced director and senior executive with 40 years’ experience in the medical innovation space He was CEO of Cochlear Limited (ASX: COH) from February 2004 to August 2015. Dr Roberts was also previously Chairman of Sirtex Medical Ltd (ASX: SRX), from March 2000 to December 2002, and was Executive Vice-President of global sleep disorder treatment company ResMed Inc (NYSE: RMD, ASX: RMD) from 1992 to 2004. Dr Roberts is a PLuS Alliance Professor appointed across 3 universities: UNSW, King’s College London and Arizona State University. Dr Roberts also sits on the boards of a number of other entities and groups including; Innovation Science Australia, Biomedical Translation Fund, Jobs for NSW, and the NHMRC’s Health Innovation Advisory Committee.
Dr. Roger Aston Non Executive Director
Dr. Roger Aston, BSc (Hons) PhD serves as a Non Executive Director of OncoSil Medical. He has had extensive experience on boards of many biotechnology and pharmaceutical companies, and has been CEO of Pitney Pharmaceuticals Ltd, pSiMedica, pSiOncology PTE Ltd, Peptech Ltd and Cambridge Antibody Technology.
In 2001, Dr Aston co-founded pSivida Limited. He served as Chief Executive Officer of Mayne Pharma Group Limited until February 15, 2012. During his career, Dr Aston has been closely involved in start-up companies and major pharmaceutical companies.
Dr Aston is currently a director and Chairman of Immuron Limited (ASX:IMC), Director and Chairman of Regeneus Limited (ASX:RGS) and Director and Chairman of ResApp Limited (ASX:RAP). Roger Aston’s principal activity is as Executive Chairman of Pharmaust Ltd (ASX:PAA).
Aspects of his experience include FDA and EU product registration, clinical trials, global licensing agreements, fundraising through private placements, and a network of contacts within the pharmaceutical, banking and stock broking sectors.
Dr Aston is both a scientist and seasoned biotechnology entrepreneur, with a successful track record in both fields. He currently has several executive and non-executive board positions with prominent biotechnology companies.
Dr Martin Cross Non-Executive Director
B.SC (Hons) and Ph.D. (Aberdeen) FAICD
Dr Cross is a highly regarded pharmaceutical executive with over 30 years’ experience including corporate and industry leadership roles directly influencing healthcare policy and government legislation in Australia and global business management, marketing and sales roles.
From 2013 to 2015, Dr Cross was Chairman of Medicines Australia, the country’s peak body representing the research based pharmaceutical industry in Australia. Prior to leading Medicines Australia, from 2010 to 2013 Dr Cross was Chairman of both the Generics Medicine Industry Association and Pharmaceutical Industry Council. During this time, Dr Cross was also Managing Director of Alphapharm in Australia and New Zealand, with responsibility for 750 employees and sales of over US $500m per annum.
From 2003 to 2008, Dr Cross was Country Head and Managing Director of Novartis Australia and New Zealand, and Head of Global Marketing and Sales Capabilities from 2001 to 2003, based in Switzerland.